Ocugen, Inc. (NASDAQ:OCGN) reported its financial results for the third quarter of 2026, revealing a net loss of 6 cents per share, excluding changes in the fair value of derivative liabilities. This result aligns with the Zacks Consensus Estimate. In comparison, the company had a loss of 7 cents per share in the same quarter the previous year.
When accounting for the change in fair value of derivative liabilities, Ocugen’s loss narrowed to 1 cent per share for the quarter. The company’s revenues increased by 11.4% year-over-year, reaching $1.95 million, which exceeded the Zacks Consensus Estimate of $1 million. Currently, Ocugen’s revenue stream is solely derived from collaboration agreements.
Following the announcement of these results, Ocugen’s stock experienced a significant rise of 17.4%. However, the stock has seen a decline of 35.2% over the year, contrasting with a 9.8% increase in the broader industry1.
Operating Expenses and Financial Position
Ocugen’s total operating expenses rose by 1.7% year-over-year to $19.7 million. Research and development (R&D) expenses increased by 12.1% to $12.5 million, up from $11.1 million in the previous year, reflecting the company’s commitment to advancing its late-stage development programs. Conversely, general and administrative expenses decreased by 12.4% to $7.2 million.
As of September 30, 2026, Ocugen reported cash, cash equivalents, restricted cash, and short-term investments totaling $84.6 million, down from $100.4 million as of June 30. The management anticipates that these funds will support operations into 2028, covering two of its three late-stage programs through their expected biologics license application (BLA) submissions2.
Pipeline Developments
Ocugen is making significant progress in its ophthalmology gene therapy pipeline, with plans for three BLA submissions by 2028. The first half of 2027 is anticipated to be particularly eventful, with top-line data expected for OCU400 and OCU410ST.
In the phase III liMeliGhT study, Ocugen completed patient enrollment for OCU400, which targets retinitis pigmentosa (RP), a rare genetic disorder that can lead to blindness. The company expects to release top-line data in the first quarter of 2027, followed by a BLA submission. Additionally, Ocugen has completed process performance qualification batches to support regulatory filings and potential commercial launches.
In October, Ocugen entered into an exclusive licensing agreement with Roots Pharmaceutical for OCU400 in the Middle East and North Africa. This agreement could yield up to $4 million in upfront and initial development milestone payments. Ocugen is also eligible for up to $255 million in potential sales milestones and a 22% royalty on net sales, with the company handling commercial supply. This marks Ocugen’s second regional licensing agreement for OCU400, following a partnership with Kwangdong Pharmaceutical in South Korea3.
The OCU410ST gene therapy for Stargardt disease is under evaluation in the pivotal phase II/III GARDian study. An independent data monitoring committee has recommended continuing the study without modifications after an interim review. Top-line data is expected in the second quarter of 2027, with a subsequent BLA submission planned.
Separately, Ocugen has initiated patient dosing in the global phase III ArMaDa3 study, which evaluates OCU410 for geographic atrophy, an advanced form of dry age-related macular degeneration. The study compares a single subretinal injection to an untreated control, measuring geographic atrophy lesion growth over 12 months as the primary endpoint. Enrollment completion is targeted for 2027, with a BLA filing anticipated in 2028, aligning with Ocugen’s broader goal of three BLA submissions by 2028.
Market Position and Competitors
Ocugen currently holds a Zacks Rank #2 (Buy). In the biotech sector, TG Therapeutics (NASDAQ:TGTX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are notable competitors, each holding a Zacks Rank #1 (Strong Buy). Over the past 60 days, TG Therapeutics’ earnings estimates for 2026 have risen from 92 cents to 94 cents per share, with 2027 estimates increasing from $2.65 to $2.66. Its stock has surged 103.8% year-to-date4.
Tarsus Pharmaceuticals’ earnings estimates for 2026 have improved from a loss of $2.41 to $2.23 per share, while 2027 estimates have increased from 58 cents to 64 cents. Despite this, Tarsus shares have declined 11.3% year-to-date.
Both TG Therapeutics and Tarsus Pharmaceuticals have experienced mixed earnings surprises in recent quarters, with TG Therapeutics having an average surprise of 184.65% and Tarsus an average negative surprise of 7.63%.
Footnotes:
- Ocugen’s stock rose by 17.4% following the earnings report, despite a year-to-date decline of 35.2%. Source.
- Ocugen’s cash reserves are expected to support operations into 2028. Source.
- Ocugen’s licensing agreement with Roots Pharmaceutical includes potential milestone payments and royalties. Source.
- TG Therapeutics’ stock has increased by 103.8% year-to-date. Source.
Featured Image: Megapixl @ Scyther5
